Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a meta-analysis of randomized controlled trials

  title={Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a meta-analysis of randomized controlled trials},
  author={Qi Wang and Xiaomei Dong and Yan Wang and Xiaobai Li},
  journal={Archives of Women's Mental Health},
The aim of this study is to meta-analytically assess the efficacy and safety of adjunctive raloxifene for postmenopausal women with schizophrenia. Six studies with 440 patients, including 225 (51.14%) patients on raloxifene and 215 (48.86%) on placebo who completed 13.71 ± 5.09 weeks of treatment, were included in this study. Meta-analysis of Positive and Negative Syndrome Scale total scores and positive, negative, and general symptom scores [standard mean difference (SMD) −0.22 to −0.55, 95… 

The effect of raloxifene augmentation in men and women with a schizophrenia spectrum disorder: a systematic review and meta-analysis

The potential of raloxifene augmentation in the treatment of schizophrenia is confirmed, and no significant effects were found for comorbid depression and cognitive functioning.

Peri- and Post-Menopausal Women with Schizophrenia and Related Disorders Are a Population with Specific Needs: A Narrative Review of Current Theories

Antipsychotic dose adjustment at menopause is recommended for schizophrenia and raloxifene may play an important role in permitting dose reduction and lessening adverse effects.

Pharmacotherapy for schizophrenia in postmenopausal women

Estrogen modulators may not help all symptoms of schizophrenia but are, nevertheless, relatively safe and, when used as adjuncts, help to keep antipsychotic doses low, thus reducing the side effect burden.

Specificity proteins 1 and 4 in peripheral blood mononuclear cells in postmenopausal women with schizophrenia: a 24-week double-blind, randomized, parallel, placebo-controlled trial

Investigation of changes in SP1 and SP4 protein levels in peripheral blood mononuclear cells suggests that SP4 may be involved in raloxifene symptom improvement in postmenopausal women and could be a potential candidate for future studies investigating blood-based biomarkers for ral oxifene effectiveness.

The association between hormones and antipsychotic use: a focus on postpartum and menopausal women

It is indicated that, within standard dose ranges, the combination of hormones and antipsychotics for postnatal and menopausal women suffering severe mental distress can be beneficial, and is safe.

Hormone Targets for the Treatment of Sleep Disorders in Postmenopausal Women with Schizophrenia: A Narrative Review

The effects of melatonin, sex hormones, and raloxifene for the treatment of insomnia in postmenopausal women with schizophrenia are explored.

Gaps or links between hormonal therapy and schizophrenia? (Review)

This mini-review is focused on the role of estrogen in the evolution of schizophrenia and on reporting trials that showed how hormonal therapy can improve the outcome of patients with schizophrenia.

Risk for midlife psychosis in women: critical gaps and opportunities in exploring perimenopause and ovarian hormones as mechanisms of risk

Abstract Women show a heightened risk for psychosis in midlife that is not observed in men. The menopausal transition (i.e. perimenopause) and accompanying changes in ovarian hormones are theorized



Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women: A Randomized Clinical Trial.

Raloxifene hydrochloride, 120 mg/d, reduces illness severity and increases the probability of a clinical response in women with refractory schizophrenia, and offers a promising, well-tolerated agent that has potential application in clinical practice.

Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: a randomized double-blind and placebo controlled trial

Raloxifene as an adjunctive treatment to risperidone was only superior in improvement of positive symptoms and it was not effective in treating negative and general psychopathology symptoms.

A Placebo-Controlled Study of Raloxifene Added to Risperidone in Men with Chronic Schizophrenia.

Raloxifene is indicated as a potential adjunctive treatment strategy for chronic schizophrenia in men in an 8-week double-blind and placebo-controlled trial.

Raloxifene as an Adjunctive Treatment for Postmenopausal Women With Schizophrenia: A 24-Week Double-Blind, Randomized, Parallel, Placebo-Controlled Trial.

In conclusion, raloxifene improved negative and general psychopathological symptoms, compared with antipsychotic medication alone, in postmenopausal women with schizophrenia.

Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age

Estradiol is an effective and clinically significant adjunctive therapy for women with treatment-resistant schizophrenia, particularly for positive symptoms, as shown in this large-scale randomized-controlled trial.

Mood effect of raloxifene in postmenopausal women.

Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia

This is the first study to show that daily, oral adjunctive raloxifene treatment at 120 mg per day has beneficial effects on attention/processing speed and memory for both men and women with schizophrenia.

Effects of raloxifene on cognition in postmenopausal women with schizophrenia: A double-blind, randomized, placebo-controlled trial

Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia

Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial.

Raloxifene at a dose of 120 mg/day, but not 60 mg/days, resulted in reduced risk of cognitive impairment in postmenopausal women.